Gossamer Bio, Inc. (GOSS)
10.11
-0.67
(-6.22%)
USD |
NASDAQ |
Oct 07, 16:00
10.30
+0.19
(+1.88%)
After-Hours: 20:00
Gossamer Bio Enterprise Value : 48.91M for Oct. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 06, 2026 | 48.91M |
| October 05, 2026 | 48.12M |
| October 02, 2026 | 48.49M |
| October 01, 2026 | 49.83M |
| September 30, 2026 | 55.45M |
| September 29, 2026 | 53.80M |
| September 28, 2026 | 53.44M |
| September 25, 2026 | 49.89M |
| September 24, 2026 | 49.83M |
| September 23, 2026 | 50.20M |
| September 22, 2026 | 54.47M |
| September 21, 2026 | 51.97M |
| September 18, 2026 | 48.61M |
| September 17, 2026 | 56.00M |
| September 16, 2026 | 50.01M |
| September 15, 2026 | 46.47M |
| September 14, 2026 | 48.43M |
| September 11, 2026 | 48.61M |
| September 10, 2026 | 52.65M |
| September 09, 2026 | 61.11M |
| September 08, 2026 | 70.99M |
| September 04, 2026 | 68.74M |
| September 03, 2026 | 68.88M |
| September 02, 2026 | 67.47M |
| September 01, 2026 | 64.88M |
| Date | Value |
|---|---|
| August 31, 2026 | 66.15M |
| August 28, 2026 | 66.20M |
| August 27, 2026 | 66.20M |
| August 26, 2026 | 68.05M |
| August 25, 2026 | 83.01M |
| August 24, 2026 | 68.59M |
| August 21, 2026 | 58.67M |
| August 20, 2026 | 60.04M |
| August 19, 2026 | 59.60M |
| August 18, 2026 | 53.00M |
| August 17, 2026 | 51.48M |
| August 14, 2026 | 58.42M |
| August 13, 2026 | 66.29M |
| August 12, 2026 | 69.86M |
| August 11, 2026 | 71.91M |
| August 10, 2026 | 69.13M |
| August 07, 2026 | 70.06M |
| August 06, 2026 | 70.25M |
| August 05, 2026 | 69.91M |
| August 04, 2026 | 71.77M |
| August 03, 2026 | 67.91M |
| July 31, 2026 | 65.90M |
| July 30, 2026 | 70.20M |
| July 29, 2026 | 84.09M |
| July 28, 2026 | 83.30M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| United Therapeutics Corp. | 20.45B |
| Arbutus Biopharma Corp. | 796.40M |
| Kura Oncology, Inc. | 442.12M |
| ACADIA Pharmaceuticals, Inc. | 2.515B |
| Alnylam Pharmaceuticals, Inc. | 29.63B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 16.90M |
| Revenue (Quarterly) | 9.238M |
| Total Expenses (Quarterly) | -7.662M |
| EPS Diluted (Quarterly) | -6.124 |
| Gross Profit Margin (Quarterly) | 97.27% |
| Earnings Yield | -550.6% |
| Normalized Earnings Yield | -615.94 |